In the Zone: iChem workflows and automation
Several challenges are driving the need for greater efficiencies and flexible iChem automation in today’s immunochemistry environment, including COVID-19 pandemic-related effects, clinical study mix, volume, and virtualization, as well as rising cost pressures on lab performance. Reconceptualization of iChem automation, including fully-integrated, scalable, and user-friendly automation platforms and a modular iChem assay development approach, are critical components to be considered to help navigate through today’s immunochemistry challenges and anticipate future industry needs.
INFOGRAPHIC
Infographic: automation considerations and solutions in disruptive times – This infographic explores iChem workflows, automation considerations and solutions in disruptive times. By comparing the historical landscape of automation verses the present landscape (post-COVID), this infographic highlights key changes and new solutions. Historically, lab staffing challenges were minimal, there were a stable volume of clinical studies and lab space was readily available for automation platforms. However, in the present landscape, COVID has led to staffing challenges, clinical study virtualization and iChem automation requires reconceptualization and significant advancement to meet today’s challenges.
PODCAST
The evolution of immunochemistry workflow automation: a podcast with Andrew Hall – In this podcast, Andrew Hall (Labcorp, UK) discusses the evolution of large molecule bioanalysis workflow automation as well as the present challenges facing the industry. He explains how the virtualization of clinical studies and its subsequent impact on sample quality have presented challenges to automation reconceptualization. He later gives his opinion on key considerations that need to be overcome when advancing the concept of automation for iChem and what the future could look like.
RESOURCES
Bioanalytical laboratory automation development: why should we and how could we collaborate?
How the COVID-19 pandemic is changing clinical trial conduct and driving innovation in bioanalysis
In association with:
